DSM: BarCap names stock a 'top pick'.
(CercleFinance.com) - Barclays Capital said on Wednesday that it has made Dutch food supplement maker DSM its "top pick," raising its target price on the shares from 73 euros to 90 euros, as the stock is set for "further outperformance in 2018.
"
The broker - which has an "outperform" rating on the shares - said it finds the group's natural sweetener stevia project and the omega-3 oil used in aquaculture very "promising."
These innovations should come in at above-average profitability and should elevate margins further, BarCap said, adding that margins have been restored, although they do not yet fully reflect the portfolio's earnings potential.
"The stock is not outright cheap anymore but we think the high-quality mid-term growth potential is not adequately priced in, yet," the broker writes in a report.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"
The broker - which has an "outperform" rating on the shares - said it finds the group's natural sweetener stevia project and the omega-3 oil used in aquaculture very "promising."
These innovations should come in at above-average profitability and should elevate margins further, BarCap said, adding that margins have been restored, although they do not yet fully reflect the portfolio's earnings potential.
"The stock is not outright cheap anymore but we think the high-quality mid-term growth potential is not adequately priced in, yet," the broker writes in a report.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.